Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Chiara Croce

Concepts (75)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pancreatic Neoplasms
10
2026
926
0.980
 Why?
Pancreatectomy
6
2026
287
0.640
 Why?
Carcinoma, Pancreatic Ductal
4
2022
293
0.500
 Why?
Adenocarcinoma
4
2026
920
0.360
 Why?
Mesenteric Artery, Superior
2
2026
28
0.270
 Why?
Neoadjuvant Therapy
3
2026
465
0.250
 Why?
Diarrhea
1
2026
193
0.220
 Why?
Antineoplastic Combined Chemotherapy Protocols
2
2026
1958
0.200
 Why?
Nomograms
1
2022
59
0.170
 Why?
Vascular Neoplasms
1
2020
18
0.150
 Why?
Pancreas
3
2020
341
0.140
 Why?
Vascular Surgical Procedures
1
2020
343
0.120
 Why?
Chemotherapy, Adjuvant
2
2026
423
0.110
 Why?
Postoperative Complications
1
2026
2961
0.100
 Why?
Pancreaticojejunostomy
1
2012
8
0.090
 Why?
Pancreatic Fistula
1
2012
35
0.090
 Why?
Neoplasm Invasiveness
2
2020
506
0.070
 Why?
Laparoscopy
1
2012
481
0.060
 Why?
Neoplasm Staging
2
2022
1467
0.060
 Why?
Arterial Occlusive Diseases
1
2007
90
0.060
 Why?
Intention to Treat Analysis
1
2026
79
0.060
 Why?
Blood Loss, Surgical
1
2007
112
0.060
 Why?
Retrospective Studies
5
2026
17247
0.060
 Why?
Organ Preservation Solutions
1
2004
46
0.050
 Why?
Middle Aged
7
2026
36126
0.050
 Why?
Humans
11
2026
145140
0.050
 Why?
Organ Preservation
1
2004
125
0.050
 Why?
Aged
5
2026
26096
0.050
 Why?
CA-19-9 Antigen
1
2022
34
0.040
 Why?
Treatment Outcome
3
2026
11741
0.040
 Why?
Tumor Burden
1
2022
324
0.040
 Why?
Portal System
1
2020
12
0.040
 Why?
Celiac Artery
1
2020
20
0.040
 Why?
Hepatic Artery
1
2020
53
0.040
 Why?
Adenocarcinoma, Mucinous
1
2020
76
0.040
 Why?
Incidence
1
2026
2915
0.040
 Why?
Proportional Hazards Models
1
2022
1325
0.030
 Why?
Male
7
2026
72664
0.030
 Why?
Female
7
2026
78636
0.030
 Why?
Comorbidity
1
2022
1657
0.030
 Why?
Prognosis
2
2020
4310
0.030
 Why?
Sex Factors
1
2022
2099
0.030
 Why?
Age Factors
1
2022
3338
0.030
 Why?
Mesocolon
1
2012
1
0.020
 Why?
Sampling Studies
1
2012
98
0.020
 Why?
Adult
5
2022
40665
0.020
 Why?
Risk Factors
1
2026
10857
0.020
 Why?
Laparotomy
1
2012
113
0.020
 Why?
Robotics
1
2012
90
0.020
 Why?
Italy
1
2009
114
0.020
 Why?
Reoperation
1
2012
630
0.020
 Why?
Adolescent
2
2022
22479
0.020
 Why?
Length of Stay
1
2012
1348
0.010
 Why?
Aged, 80 and over
2
2009
8318
0.010
 Why?
Young Adult
1
2022
14176
0.010
 Why?
Raffinose
1
2004
29
0.010
 Why?
Disaccharides
1
2004
21
0.010
 Why?
Mannitol
1
2004
40
0.010
 Why?
Allopurinol
1
2004
70
0.010
 Why?
Histidine
1
2004
66
0.010
 Why?
Glutamates
1
2004
66
0.010
 Why?
Pancreas Transplantation
1
2004
71
0.010
 Why?
Electrolytes
1
2004
54
0.010
 Why?
Adenosine
1
2004
255
0.010
 Why?
In Vitro Techniques
1
2004
1048
0.010
 Why?
Follow-Up Studies
1
2012
5411
0.010
 Why?
Glutathione
1
2004
370
0.010
 Why?
Risk Assessment
1
2012
3740
0.010
 Why?
Safety
1
2004
357
0.010
 Why?
Genetic Testing
1
2005
480
0.010
 Why?
Tissue Donors
1
2004
419
0.010
 Why?
Pilot Projects
1
2004
1889
0.010
 Why?
Genetic Predisposition to Disease
1
2005
2351
0.010
 Why?
Insulin
1
2004
2510
0.010
 Why?
Prospective Studies
1
2004
8035
0.010
 Why?
Croce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (75) concept(s)
_
Co-Authors Expand Description
See all (10) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)